GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LCTX · Sep 30, 2024

Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000950170-24-127077General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.96% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generation88thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-153.14% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

203.29% · CORE · NOT_ENOUGH_HISTORY

Operating margin100thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-101.61% · CORE · VALID

R&D intensity0thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

83.91% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

35.19% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
3.55%
Current
2.96%
Delta
-0.59%
Cash Generation Increased
Previous
-367.61%
Current
-153.14%
Delta
214.48%
Growth Increased
Previous
-56.34%
Current
203.29%
Delta
259.63%
Profitability Increased
Previous
-416.69%
Current
-101.61%
Delta
315.08%
R And D Intensity Decreased
Previous
203.69%
Current
83.91%
Delta
-119.78%
Sbc Intensity Decreased
Previous
90.13%
Current
35.19%
Delta
-54.93%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.